FDA Opens Early Access to Novel Pancreatic Cancer Drug Generating Buzz

(MedPage Today) -- The FDA has given the green light to an expanded access program (EAP) for the investigational pancreatic cancer drug daraxonrasib. In a "safe to proceed" letter to Revolution Medicines, the FDA gave its approval to initiate...
Source
MedPage Today
Opens original article in a new tab



